-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Benzinga·07/24/2026 14:46:25
Listen to the news
Stifel analyst Dara Azar maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $45 to $38.